journal article·2025-07

Co-assembly of oligo-urethane nanoparticles with defined lipid additives to tailor RNA delivery into cells

Suja Shrestha, Elaine Yan, Beining Yang, Aled Blundell, Allen C.T. Teng, Ryan M. Marks, Ronald Cohn, Evgueni Ivakine, Anthony O. Gramolini, J.Paul Santerre

Acta Biomaterialia· Volume 201
Publisher page

Abstract

Developing safe and effective biomaterials to deliver RNA into cells has grown in importance over recent years and has enabled the clinical translation of several gene therapies. Self-assembled oligo-urethane nanoparticles (PNPs) have several advantageous properties, such as (1) mitigating immune cell response in vivo, (2) low cytotoxicity in a broad range of cells, and (3) capable of delivering oligonucleotides or proteins into cells. Here, we were interested in defining unique configurations of PNPs to assess their relative cytotoxicity to human cells, comparing them to a popular commercial lipid system MessengerMax, as some cationic lipids have been found to have associated toxicity, instigating the search for less toxic counterparts. This was then followed by demonstrating the ability of enhanced green fluorescent protein (EGFP) mRNA to be loaded onto the PNPs, and to establish methods to enable the efficient transgene expression in a number of cell types, including Caco-2 and C2C12 cells which are known to be difficult-to-transfect cells. The addition of small amounts of PEGylated lipid to PNP significantly increased EGFP expression in HEK293T cells, Caco-2 cells and C2C12 cells at an effective mRNA/PNPs ratio (wt/wt) of 1:40, while the addition of the ionizable cationic lipid, significantly increased EGFP expression in C2C12 cells and differentiated C2C12 cells (myofibers) at mRNA/PNPs ratio (wt/wt) of 1:125, while keeping PNPs mass constant to 62.5 μg and changing the mRNA mass. Our study demonstrated that lipid-assisted, PNP-mediated mRNA delivery achieved a high transfection efficiency in terminally differentiated myofibers, paving the way for potential innovative therapeutics, e.g. targeted to muscular dystrophies. STATEMENT OF SIGNIFICANCE: There are reports of diverse delivery agents for RNA, but there is still unmet need for more versatile, and safe delivery vehicles. In this study we demonstrated that when compared to MessengerMax (a lipid-based mRNA transfection reagent), self-assembled oligo-urethane nanoparticle (PNP) showed favorable cell viability. The scope of PNP as a RNA delivery vehicle was extended beyond HEK293T cells by showing transfections into a number of cell types. The addition of select lipids to PNPs, significantly increased EGFP expression in difficult-to-transfect cells: Caco-2 (2.9-fold), C2C12 (1.4-fold) and differentiated C2C12 (1.28-fold) cells when compared to PNPs. These findings indicate that select lipid incorporation on PNPs provide a promising strategy to improve the efficacy of RNA therapeutics for diseases in clinical applications.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. Optimizing cardiac delivery of modified mRNA10.1016/j.ymthe.2017.03.016 ↗
2. mRNA-based therapeutics–developing a new class of drugs10.1038/nrd4278 ↗
3. Drug delivery systems for RNA therapeutics10.1038/s41576-021-00439-4 ↗
4. mRNA delivery via non-viral carriers for biomedical applications10.1016/j.ijpharm.2021.121020 ↗
5. Three decades of messenger RNA vaccine development10.1016/j.nantod.2019.100766 ↗
6. Tmem65 is critical for the structure and function of the intercalated discs in mouse hearts10.1038/s41467-022-33303-y ↗
7. Proteomics and phosphoproteomics of failing human left ventricle identifies dilated cardiomyopathy-associated phosphorylation of CTNNA310.1073/pnas.2212118120 ↗
8. Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER10.1038/sj.gt.3300604 ↗
9. Non-viral approaches to gene therapy10.1093/oxfordjournals.bmb.a072953 ↗
10. Endocytosis: the nanoparticle and submicron nanocompounds gateway into the cell10.3390/pharmaceutics12040371 ↗
11. Strategies for the intracellular delivery of nanoparticles10.1039/C0CS00003E ↗
12. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
13. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
14. Advances in lipid nanoparticles for siRNA delivery10.3390/pharmaceutics5030498 ↗
15. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective10.1021/acs.bioconjchem.3c00174 ↗
16. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing10.1038/s41565-020-0669-6 ↗
17. High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models10.1038/s41467-024-45422-9 ↗
18. Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery10.1038/s41565-024-01747-6 ↗
19. Understanding the biodegradation of polyurethanes: from classical implants to tissue engineering materials10.1016/j.biomaterials.2005.05.079 ↗
20. Self-assembled oligo-urethane nanoparticles: their characterization and use for the delivery of active biomolecules into mammalian cells10.1021/acsami.1c17868 ↗
21. Bioinspired oligo-urethane nanoparticles for delivering exogenous C-type natriuretic peptide: synthetic biomaterial nanocarrier complexes and their interactions with cardiac myofibroblasts10.1021/acs.biomac.3c00210 ↗
22. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent In vivo genome editing10.1016/j.celrep.2018.02.014 ↗
23. Limited endothelial plasticity of mesenchymal stem cells revealed by quantitative phenotypic comparisons to representative endothelial cell controls10.1002/sctm.18-0127 ↗
24. Mitigating the non-specific uptake of immunomagnetic microparticles enables the extraction of endothelium from human fat10.1038/s42003-021-02732-8 ↗
25. Back to basics: optimization of DNA and RNA transfer in muscle cells using recent transfection reagents10.1016/j.yexcr.2022.113392 ↗
26. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells10.1016/j.jconrel.2022.05.020 ↗
27. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways10.1021/nn700256c ↗
28. Nanomaterial cytotoxicity is composition, size, and cell type dependent10.1186/1743-8977-7-22 ↗
29. Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting10.1002/anie.201309464 ↗
30. Optimized conditions for successful transfection of human endothelial cells with in vitro synthesized and modified mRNA for induction of protein expression10.1186/1754-1611-8-8 ↗
31. Strong immune responses induced by direct local injections of modified mRNA-lipid nanocomplexes10.1016/j.omtn.2019.12.044 ↗
32. Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides10.3390/molecules23102564 ↗
33. Caco-2 cells for measuring intestinal cholesterol transport - possibilities and limitations10.1186/s12575-020-00120-w ↗
34. Transfection of cultured myoblasts in high serum concentration with DODAC:DOPE liposomes10.1038/sj.gt.3300729 ↗
35. Poly(ester amine) constructed from polyethylenimine and pluronic for gene delivery in vitro and in vivo10.3109/10717544.2016.1162877 ↗
36. Cellular uptake of nanoparticles: journey inside the cell10.1039/C6CS00636A ↗
37. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine10.1016/j.addr.2019.04.008 ↗
38. Effect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticles10.1007/s11051-013-1874-0 ↗
39. Imaging and inhibition of multi-drug resistance in cancer cells via specific association with negatively charged CdTe quantum dots10.1016/j.biomaterials.2010.02.053 ↗
40. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy10.1016/j.biomaterials.2014.05.068 ↗
41. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant10.1021/nl803487r ↗
42. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration10.1038/s42003-021-02441-2 ↗
43. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines10.1371/journal.pone.0024438 ↗
44. Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina10.1038/s41467-023-42189-3 ↗
45. Effect of pegylation on pharmaceuticals10.1038/nrd1033 ↗